Wealth Enhancement Advisory Services
VIR icon

Wealth Enhancement Advisory Services’s Vir Biotechnology VIR Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$227K Sell
22,821
-2,498
-10% -$23.8K ﹤0.01% 3472
2026
Q1 		$229K Buy
25,319
+14,572
+136% +$116K ﹤0.01% 3023
2025
Q4 		$64.1K Sell
10,747
-318
-3% -$1.89K ﹤0.01% 3507
2025
Q3 		$62.6K Sell
11,065
-4,928
-31% -$25.2K ﹤0.01% 3399
2025
Q2 		$86.5K Buy
15,993
+4,031
+34% +$21.6K ﹤0.01% 3160
2025
Q1 		$77.5K Buy
+11,962
New +$106K ﹤0.01% 2807

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wealth Enhancement Advisory Services's VIR Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Vir Biotechnology (VIR) stake by 9.9% in Q2 2026, selling an estimated $23.8K and leaving 22,821 shares worth $227K. The position accounts for ﹤0.01% of the portfolio, ranked #3472.

Wealth Enhancement Advisory Services first reported a position in VIR in Q1 2025 and has held it in 6 quarters since. The position peaked at $229K in Q1 2026. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Wealth Enhancement Advisory Services held 22,821 shares of Vir Biotechnology worth $227K as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 2,498 Vir Biotechnology shares in Q2 2026, an estimated $23.8K.
  • Vir Biotechnology made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3472 holding.
  • Wealth Enhancement Advisory Services first reported a position in Vir Biotechnology in Q1 2025 and has held it in 6 quarters since.
  • Wealth Enhancement Advisory Services's Vir Biotechnology position peaked at $229K in Q1 2026.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.